8-K: BioRestorative Therapies Enters $3.6 Million At-The-Market Offering Agreement

BioRestorative Therapies has entered into an agreement to potentially sell up to $3.6 million of its common stock through an at-the-market offering.

Summary

• BioRestorative Therapies, Inc. has entered into an At The Market Offering Agreement with Rodman & Renshaw LLC.
• The company may offer and sell shares of its common stock, with an aggregate offering price of up to approximately $3.6 million.
• The company is not obligated to sell any shares under this agreement.
• Rodman & Renshaw will use commercially reasonable efforts to sell shares based on the company's instructions.
• The agent will receive a 3.0% commission on the gross sales proceeds.
• The offering will terminate when the shares are sold or the agreement is terminated.
• The shares will be issued under an existing registration statement filed with the SEC.
• A previous agreement with JonesTrading Institutional Services LLC for a similar offering was terminated on November 1, 2024, after $622,235 of shares were sold.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard financial transaction for a company to raise capital. While it introduces potential dilution, it also provides financial flexibility.

Positives

• The company has secured a new avenue for potential capital raising through the at-the-market offering.
• The agreement provides flexibility, as the company is not obligated to sell any shares.
• The company has terminated a previous agreement, streamlining its capital raising efforts.

Negatives

• The company will incur a 3.0% commission on any shares sold through the offering.
• The company is not guaranteed to raise the full $3.6 million, as sales are dependent on market conditions and the agent's efforts.

Risks

• The company's stock price could be negatively impacted by the potential increase in the number of shares available in the market.
• There is no guarantee that the company will be able to sell all the shares at the desired price or at all.
• The company is reliant on the agent's efforts to sell the shares.

Future Outlook

The company intends to use the proceeds from the offering for general corporate purposes, but the specific use of funds is not detailed in this document.

Management Comments

• The company's President and CEO, Lance Alstodt, signed the agreement on behalf of BioRestorative Therapies, Inc.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This allows companies to sell shares gradually into the market, potentially minimizing the impact on the stock price compared to a traditional secondary offering.

Comparison to Industry Standards

• The 3% commission is within the typical range for at-the-market offerings.
• The size of the offering, $3.6 million, is relatively small compared to some larger biotech companies, but is not unusual for a company of BioRestorative Therapies' size and stage.
• Comparable companies that have used at-the-market offerings include XOMA Corporation and Agenus Inc, which have raised capital through similar agreements.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company may have more capital to fund operations and research.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• The company will potentially sell shares of its common stock through Rodman & Renshaw.
• The company will monitor market conditions and determine the timing and amount of shares to be sold.
• The company will file necessary reports with the SEC regarding the offering.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Rodman & Renshaw, BioRestorative Therapies, securities, sales agreement